Cytokinetics (CYTK) Commences Third CK-2017357 Phase II

Cytokinetics, Inc. (Nasdaq: CYTK) announced today that the company has opened enrollment in a third Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS). CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input and delays the onset and reduces the degree of muscle fatigue. CK-2017357 is the lead drug candidate that has emerged from the company's skeletal muscle contractility program.

Click here for more from the release.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Home Depot expands executive roles, grants $500K in restricted stock
• Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026